FATE

0.95045.90%
MC

Matthew C. Abernethy

Chief Financial Officer

Mr. Matthew C. Abernethy, also known as Matt, C.P.A., serves as Independent Director of Fate Therapeutics, Inc. from May 29, 2025. Mr. Abernethy has been the Chief Financial Officer at Neurocrine Biosciences, Inc. since November 29, 2017. Mr. Abernethy has experience in the financial sector and investor relations with expertise in the healthcare industry. Mr. Abernethy served as the Principal Financial Officer and Vice President of Global Finance at Biomet Orthopedics, LLC and Biomet U.S. Reconstruction, LLC. Mr. Abernethy served as Vice President of Investor Relations and Treasurer of Zimmer Biomet Holdings, Inc. until November 2017. He joined Neurocrine from Zimmer Biomet, where he held various positions from February 2009 to November 2017, over the past nine years including Vice President of Finance for the Americas and Global Product Engines. He began his career with KPMG LLP and is a certified public accountant. Mr. Abernethy earned his B.S. in Accounting and Business Administration from Grace College and an MBA from the University of Chicago.

公司職務